AR-V7 TEST - Key Persons

Job Titles:

• Vice President, Product Strategy

As Vice President, Product Strategy, Ms. Tubbs has over 20 years of broad industry experience successfully developing technology solutions as well as bringing global products to market. Her expertise driving strategy in the diagnostic space spans from concept creation to address unmet medical needs through clinical evidence build and market access. She has established collaboration and program management teams and processes within top Pharmaceutical companies such as Roche and AstraZeneca and is committed to improving cancer patient care through innovation.

Amara Siva, Ph.D. joined Epic Sciences as the Vice President of Lab Operations in 2021. Dr. Siva has over 20 years of molecular diagnostic development experience, including assay development from concept stage to clinical validation, and the launch and scaling of molecular and immunologic diagnostic tests into commercial clinical laboratories as well as implementation into global clinical trials. Prior to joining Epic Sciences, Dr. Siva served in leadership roles in CLIA laboratory operations management, clinical trials, and research at companies including Pathnostics, Millennium Health, Genoptix/Novartis, Gen-Probe, and Alexion. Dr. Siva received her B.S. in Biochemistry and Cell Biology from UC San Diego and Ph.D. in Biological Chemistry from UCLA. She is an ASQ-certified Six Sigma Green Belt, holds a Clinical Genetic Molecular Biologist Scientist license in the State of California, and is certified as a High-complexity Clinical Laboratory Director by the American Board of Bioanalysis.

Jason Christiansen, Ph.D., joins Epic Sciences as CTO bringing 20 years of experience in developing new technologies and the strategies for their uses in research, clinical diagnostics and targeted therapy development. Jason joins Epic from Boundless Bio, where he served as CTO and oversaw development of methods for the identification and characterization of extrachromosomal DNA; combining biological visualization, image analysis and structural biology to identify specific tumor types and patient populations. Prior to that, he was the head of assay development at Roche Sequencing Solutions, providing leadership in initiatives around oncology testing, diagnostics development, NIPT testing and platform development. Jason was vice president of diagnostics at Ignyta, later purchased by Roche/Genentech, where he led CDx development strategies and implementation, including an on-site CLIA laboratory and molecular testing R&D group working both internally and externally to drive molecular testing in support of a global clinical trial for Rozlytrek (entrectinib). These efforts produced one of the earliest Expedited Access Pathway (Breakthrough Diagnostic) designations for the Ignyta RNA next generation sequencing test. As the senior director of assay development at Genoptix (Novartis), Jason led efforts to introduce new technology products, including NGS and digital pathology (routine and immunofluorescence), into the clinical laboratory for commercial and pharma applications. At HistoRx, Jason was a leader in the development of a quantitative immunofluorescence imaging platform, including assay, hardware, and software components, for clinical diagnostic testing and pharma applications. Jason holds a B.S. in physics from the University of California, Davis and a joint Ph.D. in Biophysics from UC Davis and Lawrence Berkeley National Laboratory.

Job Titles:

• Chief Financial Officer
• General Counsel

Joel Smith serves as Chief Financial Officer and General Counsel at Epic Sciences. A veteran legal professional with more than 20 years of experience in the life sciences and biopharmaceutical industries, Mr. Smith brings a breadth of knowledge in strategic corporate development, complex commercial transactions, licensing, securities law, corporate governance and regulatory compliance. Smith has served as a senior executive and general counsel for a number of biotechnology and life sciences companies, including BioQ, Triad Therapeutics, and Sientra, Inc. At Sientra, Smith was responsible for all of its legal affairs including corporate compliance, commercialization policies, and intellectual property. He was a primary contributor to its premarket application for FDA approval of its implants and in the preparation of the prospectus used in its initial public offering on Nasdaq. Most recently, Smith was the managing counsel of Qualcomm Life, the medical device subsidiary of Qualcomm where he and his team supported global sales and business development teams. Smith earned his Juris Doctorate, cum laude, and a Master of Business Administration, with highest distinction, from the University of Michigan, as well as a Bachelor of Science in Cellular and Molecular Biology and Economics. He is a member of the State Bar of California.

Job Titles:

• Epic Sciences As President and Chief Executive Officer

Lloyd Sanders joined Epic Sciences as President and Chief Executive Officer in 2019 with more than 20 years of diagnostics and pharmaceutical industry experience, most of it focused on oncology. Prior to joining Epic, he served as president of the oncology segment of Myriad Genetics, overseeing the oncology, urology and dermatology commercial organizations. While at Myriad, he was responsible for the sales, marketing, medical, customer service and laboratory operations for numerous market-leading commercial products, including molecular diagnostics for risk assessment, diagnosis/screening, prognosis and selection of therapies for breast, prostate, colorectal and other cancers. Previously, Mr. Sanders served as chief operating officer at Dey Pharma, a division of Mylan, overseeing sales, marketing and medical affairs, including the EpiPen® flagship brand. Prior to Dey Pharma, he held several leadership positions including responsibility for the commercial growth of a number of oncology products at Sanofi-Synthelabo, subsequently Sanofi-Aventis, where he led the successful restructuring and integration of two companies' sales forces after the merger. Mr. Sanders started his pharmaceutical career and participated in oncology product launches at Pharmacia (now Pfizer). Mr. Sanders earned a Bachelor's business degree with an emphasis in marketing from Memphis State University.

Job Titles:

• Dean 's Professor of Biological Sciences
• Founder and Chief Scientific Advisor at Epic Sciences

Peter Kuhn, PhD, is Founder and Chief Scientific Advisor at Epic Sciences. He is the principal architect of the Epic Sciences platform and has invested his career into the research, development, and the clinical utility of the liquid biopsy. His vision of translating innovation in research to meaningful products for patient care is driving his everyday efforts. Dr. Kuhn is the Dean's Professor of Biological Sciences, Professor of Medicine, Aerospace & Mechanical Engineering, and Biomedical Engineering at the University of Southern California. He also serves as the Director of the USC Michelson Convergent Science Institute in Cancer (CSI-Cancer) and the deputy director of the Convergent Science - Virtual Cancer Center. He holds a chair as Honorary Professor of Cancer Science at the University of Manchester in the United Kingdom. Previously, Dr. Kuhn held faculty appointments at The Scripps Research Institute and at Stanford University. While at Stanford, Dr. Kuhn established the structural genomics research enterprise and focused his research on technology developments in structural biology that were utilized by breakthrough research such as Dr. Roger Kornberg's (Nobel prize 2006) structure determination of the RNA Polymerase. Dr. Kuhn joined Scripps and advanced technologies that led to the structure determination of the human b2AR GPCR with collaborators including Dr. Brian Kobilka (Nobel prize 2012). Dr. Kuhn is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 including research with Drs. Michael Radermacher and Joachim Frank (Nobel prize 2017) in electron microscopy and his Ph.D. in 1995 with Dr. Patrick VanRoey in X-ray crystallography. He then moved to Stanford University where he joined the faculties of Medicine and Accelerator Physics as tenure track Assistant Professor. From 2002 to 2014 he established the Physics Oncology program at The Scripps Research in La Jolla, CA as tenured Associate Professor before joining USC in 2014. His research and inventions have resulted in over 300 peer-reviewed publications, which have been cited over twenty-thousand times.